# SafeHeal: Medical Device Innovator in Colorectal Surgery
SafeHeal is a clinical-stage medical device manufacturer focused on solving a critical problem in colorectal surgery: preventing anastomotic leaks and complications after surgical resection[1]. The company's flagship product, Colovac, is an endoluminal bypass sheath designed to eliminate the need for temporary diverting ostomies—artificial openings that require patients to wear pouches during recovery[2][5].
The company serves colorectal surgeons and their patients, addressing a substantial clinical need: approximately 20-30% of colorectal surgery patients experience adverse events related to anastomotic complications, many unable to proceed with ostomy reversal procedures[5]. SafeHeal's solution is minimally invasive, fully reversible, and allows patients to resume normal life without external pouches during the healing process[3].
SafeHeal was founded in 2015 based on the invention of French surgeon Dr. Khosrovani[5]. The company was the first company created and incubated by MD Start II, Sofinnova Partners' in-house medtech accelerator, which provides hands-on entrepreneurial expertise to early-stage medical device startups[3]. This accelerator backing positioned SafeHeal within a robust ecosystem of clinical innovation from its inception.
The company is headquartered in Paris, France, with a wholly owned U.S. subsidiary in Tampa, Florida[4]. This dual-geography structure reflects the company's strategy to pursue regulatory approval and commercialization across both European and North American markets.
SafeHeal operates at the intersection of medtech innovation and unmet clinical needs in a high-stakes surgical domain. The colorectal cancer surgery market is substantial and growing, yet the standard-of-care approach (temporary ostomies) carries significant patient burden and healthcare costs[5].
The company's timing is advantageous: regulatory pathways for innovative medical devices have matured, reimbursement discussions around novel surgical solutions are increasingly sophisticated, and healthcare systems are actively seeking solutions that reduce complications and improve patient outcomes[2]. SafeHeal's CEO has been positioned to address Medicare reimbursement strategies at major medtech conferences, signaling the company's readiness to engage payers[2].
The company also benefits from the broader medtech acceleration ecosystem pioneered by firms like Sofinnova, which provide not just capital but operational expertise, regulatory guidance, and market access—critical advantages for navigating the complex path from clinical innovation to commercialization[3].
SafeHeal stands at an inflection point. With EU regulatory approval secured and an active FDA pivotal study underway, the company is transitioning from clinical validation to commercialization[1][4]. The oversubscribed Series C and subsequent €10M extension suggest strong investor conviction in the market opportunity and execution capability.
The next critical milestones are FDA approval in the U.S. market and successful reimbursement negotiations with major payers. If Colovac gains traction in Europe and achieves FDA clearance, the company could capture significant market share in a procedure performed hundreds of thousands of times annually. The broader trend favoring patient-centric, minimally invasive alternatives to traditional surgical approaches works in SafeHeal's favor, positioning the company to influence how colorectal surgery is practiced globally.
SafeHeal has raised $97.0M in total across 3 funding rounds.
SafeHeal's investors include Asabys Partners, Soffinova Partners, EQT Life Sciences, Forbion.
SafeHeal has raised $97.0M across 3 funding rounds. Most recently, it raised $12.0M Series C in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $12.0M Series C | Asabys Partners, Soffinova Partners | |
| Apr 1, 2025 | $40.0M Series C | EQT Life Sciences, Forbion, Soffinova Partners | |
| Jan 1, 2022 | $45.0M Series B | EQT Life Sciences, Forbion, Soffinova Partners |
